NJ Wazaney is a seasoned MedTech executive with over 35 years of experience leading growth initiatives across both start-ups and Fortune 500 companies. A visionary leader with deep expertise in healthcare and health IT, NJ has consistently driven business transformation by launching innovative technologies, scaling companies, and building high-performing teams across diverse markets.

He has provided strategic leadership and operational oversight across all facets of business—governance, mission, services, and revenue development—ensuring long-term financial stability and market success. NJ has a strong track record of implementing go-to-market strategies that outperform the competitive landscape and unlock new pathways for revenue generation.

His most recent leadership roles include:

• EVP Strategy of Vizium360 where he spearheaded platform growth and M&A strategy in the aesthetics space.

• CEO of Blue Ocean Aesthetics Holdings (Private Equity-backed), where he spearheaded platform growth and M&A strategy in the aesthetics space.

• CEO of Rohrer Aesthetics an Energy-Based Device company in the aesthetic market.

• VP of Alliances & Partnerships at Merz Aesthetics, where he served on the North American Leadership Team, forging key commercial partnerships and expansion initiatives.

• CEO of Symplast, a SaaS EMR and practice management company, where he led product and market transformation.

• VP of Corporate Accounts at Ulthera (acquired by Merz), overseeing national sales and channel development.

Earlier in his career, NJ held progressive sales and leadership roles at industry leaders such as TYRX (Medtronic), IDEV Technologies (Abbott), Cardiva Medical (Haemonetics), BARD, CardioDynamics, and Kimberly-Clark/Ballard Medical.

NJ brings a unique combination of boardroom leadership and commercial execution, helping organizations at critical inflection points innovate, scale, and lead.